Coleman Rotstein
Dr. Coleman Rotstein, MD, FRCPC, FACP, FIDSA is a Canadian infectious diseases specialist based in Toronto, Ontario. He is notable in the COVID-19 pandemic due to his role in approving the initial COVID-19 vaccines as a part of the National Advisory Committee on Immunization (NACI).
Education
Rotstein received a Bachelor of Science at the University of Toronto and earned his medical degree from the University of Calgary in 1976. He completed his specialty training in Internal Medicine at the University of Toronto and pursued further subspecialty training in Infectious Diseases & Immunology at the Medical University of South Carolina in Charleston, South Carolina from 1980 to 1983.
Affiliations
Rotstein served as a member of the National Advisory Committee on Immunization (NACI), and participated in the initial authorization of COVID-19 vaccines in Canada.1)
He is the former Director of the Division of Infectious Diseases at McMaster University, past Chair and Secretary of the Infectious Diseases Section of the Ontario Medical Association, former Co-chair of the Emerging Infectious Diseases Network, former Past-President of the Association of Medical Microbiology and Infectious Disease Canada, former President of the Canadian Infectious Disease Society, and former Chair of the Clinical Trials Committee of the Canadian Infectious Disease Society. In addition, he has been elected a fellow of the American College of Physicians and the Infectious Diseases Society of America. He is a reviewer for several international journals and was formerly Associate Editor, Review Section, for the Canadian Journal of Infectious Diseases and Medical Microbiology, and for Biomed Central Infectious Diseases.
He is a Professor of Medicine in the Division of Infectious Diseases at the University of Toronto, and an Attending Physician and Director of Oncologic Infectious Diseases of the Immunocompromised Host Infectious Diseases Service at the University Health Network.2) 3) UHN receives funding from a range of pharmaceutical companies including Amgen, Apotex, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Eli Lilly, EMD Serono, Epizyme, GlaxoSmithKline, Immunex, Janssen, Merck, Onyx, Pfizer, Roche, Sanofi, and Teva.4)
He is a faculty member for Mentoring in IBD, an annual education program for Canadian gastroenterologists.5) It is currently funded by AbbVie, Amgen, Bristol-Myers Squibb, Janssen, Organon, Pfizer, Sandoz, and Takeda.6)
Research
Rotstein has published over 160 peer-reviewed papers. His research interests have focused mainly on infections in cancer patients and other immunocompromised hosts as well as fungal infections caused by Candida organisms. He maintains active research interests in clinical trials involving antifungal agents in immunocompromised hosts.
Funding
Rotstein has received grants from Astellas, Chimerix, Cidara Therapeutics, Merck, Pfizer, and other funding (including personal, consulting and speaking fees) from Avir Pharma, Merck, Pendopharm, Pfizer, Roche, Sunovion, and Teva.7) 8)
Media
Presentations
Rotstein was a speaker at the 2021 Winter Hematology Update hosted by the CARE Faculty, where he presented on the topic of COVID-19 vaccines in oncology patients.9) 10) The event was sponsored by AbbVie, AstraZeneca, Beigene, Bristol-Myers Squibb, Janssen, and Kite Pharma (a Gilead Sciences company).11)